Inventor · disambiguated record
Kiyoshi Tachikawa
Also filed as: TACHIKAWA KIYOSHI
26 granted patents·18 pending applications·52 citations·filing 2008–2024
94Inventor score
Top patents by PatentIndex Score
44 records- 0195US11744887B2Coronavirus vaccine compositions and methodsARCTURUS THERAPEUTICS INC·Filed 2021·Granted Sep 5, 2023·4 cites·28 claims
- 0294US12220455B2Coronavirus vaccine compositions and methodsARCTURUS THERAPEUTICS INC·Filed 2023·Granted Feb 11, 2025·1 cites·33 claims
- 0393US10815463B2Messenger UNA molecules and uses thereofARCTURUS THERAPEUTICS INC·Filed 2017·Granted Oct 27, 2020·6 cites·19 claims
- 0492US9856475B2Formulations for treating amyloidosisARCTURUS THERAPEUTICS INC·Filed 2015·Granted Jan 2, 2018·5 cites·18 claims
- 0590US11685906B2Compositions and methods for treating ornithine transcarbamylase deficiencyARCTURUS THERAPEUTICS INC·Filed 2019·Granted Jun 27, 2023·4 cites·25 claims
- 0689US11015204B2Synthesis and structure of high potency RNA therapeuticsARCTURUS THERAPEUTICS INC·Filed 2018·Granted May 25, 2021·6 cites·28 claims
- 0789US2025161434A1Coronavirus vaccine compositions and methodsARCTURUS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0888US12390524B2Compositions and methods for inducing immune responsesARCTURUS THERAPEUTICS INC·Filed 2023·Granted Aug 19, 2025·0 cites·22 claims
- 0988US11759515B2Compositions and methods for inducing immune responsesARCTURUS THERAPEUTICS INC·Filed 2021·Granted Sep 19, 2023·1 cites·27 claims
- 1088US10369232B2Allele selective gene editing and uses thereofARCTURUS THERAPEUTICS INC·Filed 2016·Granted Aug 6, 2019·14 cites·25 claims
- 1186US10421964B2UNA oligomers and compositions for treating amyloidosisARCTURUS THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·2 cites·16 claims
- 1285US12070509B2Nucleic acids and methods of treatment for cystic fibrosisARCTURUS THERAPEUTICS INC·Filed 2021·Granted Aug 27, 2024·1 cites·34 claims
- 1385US9982259B2Transthyretin allele selective UNA oligomers for gene silencingARCTURUS THERAPEUTICS INC·Filed 2015·Granted May 29, 2018·5 cites·29 claims
- 1484US12398379B2Compositions and methods for treating ornithine transcarbamylase deficiencyARCTURUS THERAPEUTICS INC·Filed 2023·Granted Aug 26, 2025·0 cites·20 claims
- 1582US12290567B2Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugatesARCTURUS THERAPEUTICS INC·Filed 2020·Granted May 6, 2025·1 cites·19 claims
- 1679US11407800B2Translatable molecules and synthesis thereofARCTURUS THERAPEUTICS INC·Filed 2018·Granted Aug 9, 2022·1 cites·19 claims
- 1778US11377643B2Therapeutics for glycogen storage disease type IIIULTRAGENYX PHARMACEUTICAL INC·Filed 2018·Granted Jul 5, 2022·1 cites·20 claims
- 1873US2025136953A1Compositions and methods for the treatment of ornithine transcarbamylase deficiencyARCTURUS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1972US2025049950A1Nucleic acids and methods of treatment for cystic fibrosisARCTURUS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2071US11939363B2Translatable molecules and synthesis thereofARCTURUS THERAPEUTICS INC·Filed 2022·Granted Mar 26, 2024·0 cites·20 claims
- 2169US12509698B2Synthesis and structure of high potency RNA therapeuticsARCTURUS THERAPEUTICS INC·Filed 2021·Granted Dec 30, 2025·0 cites·18 claims
- 2266US2022340886A1Therapeutics for glycogen storage disease type iiiULTRAGENYX PHARMACEUTICAL INC·Filed 2022·Application pending·0 cites
- 2365US12351834B2Compositions and methods for the treatment of ornithine transcarbamylase deficiencyARCTURUS THERAPEUTICS INC·Filed 2021·Granted Jul 8, 2025·0 cites·37 claims
- 2465US11685921B2Molecules and agents for treating hepatitis B virusARCTURUS THERAPEUTICS INC·Filed 2019·Granted Jun 27, 2023·0 cites·11 claims
- 2564US10604758B2Therapeutic oligomers for treating amyloidosisARCTURUS THERAPEUTICS INC·Filed 2017·Granted Mar 31, 2020·0 cites·18 claims
- 2664US2025000957A1Compositions and methods for treating phenylketonuriaARCTURUS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2762US10683500B2UNA oligomers having reduced off-target effects in gene silencingARCTURUS THERAPEUTICS INC·Filed 2018·Granted Jun 16, 2020·0 cites·10 claims
- 2862US2024316090A1Transcription activator-like effector nucleases (talens) targeting hbvARCTURUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2960US2023159449A1Lipid formulations containing nucleic acids and methods of treatment for cystic fibrosisARCTURUS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3059US2023219996A1Rna vaccinesARCTURUS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3157US2023323345A1Una oligomers for the treatment of polyglutamine diseasesARCTURUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3254US8552168B2Nucleic acids for inducing expression of transcripts and proteins and methods for making and using themBRIGGS STEVEN P·Filed 2008·Granted Oct 8, 2013·0 cites·18 claims
- 3354US2024309366A1Compositions and methods for treating metabolic disordersARCTURUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3452US2023227826A1Una oligomers for the treatment of polyglutamine diseasesARCTURUS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3552US2022096520A1Modified proteins and associated methods of treatmentARCTURUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3651US10961535B2Compositions and agents against hepatitis B virus and uses thereofARCTURUS THERAPEUTICS INC·Filed 2018·Granted Mar 30, 2021·0 cites·18 claims
- 3751US2010316702A1Compositions and methods for regulating erythropoeitin expression and ameliorating anemia and stimulating erythropoiesisUNIV CALIFORNIA·Filed 2009·Application pending·0 cites
- 3851US2017137821A1Molecules and agents for treating hepatitis b virusARCTURUS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3948US11939600B2Compositions and methods for treating phenylketonuriaARCTURUS THERAPEUTICS INC·Filed 2018·Granted Mar 26, 2024·0 cites·14 claims
- 4046US10519447B2Therapeutic UNA oligomers and uses thereofARCTURUS THERAPEUTICS INC·Filed 2016·Granted Dec 31, 2019·0 cites·9 claims
- 4144US2021292768A1Compositions and agents against nonalcoholic steatohepatitisARCTURUS THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4243US2017016000A1Compositions and agents against hepatitis b virus and uses thereofARCTURUS THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4343US2016130567A1Messenger una molecules and uses thereofARCTURUS THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4442US2015307881A1Una oligomers having reduced off-target effects in gene silencingARCTURUS THERAPEUTICS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kiyoshi Tachikawa files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →